Dr. Xiaofei Wang
Duke University Medical Center, USA
Email: xiaofei.wang@duke.edu
Qualifications
2003 Ph.D., University of North Carolina
1999 M.Sc., University of North Carolina
1993 M.Sc., Peking University
1990 B.Sc., East China Normal University
Publications (selected)
-
AT Schroen, GR
Petroni, H Wang, M Thielen, R Gray, B Djulbegovic, XF Wang, DJ Sargent, J Benedetti,
W Cronin, L Wickerham, A Denicoff, CL Slingluff (2010). Preliminary Evaluation
of Factors Associated with Premature Trial Closure and Feasibility of Accrual
Benchmarks in Phase III Oncology Trials. Clinical Trials7(4), 312-321; PMID:
20595245.
-
S Dubey, P
J¨anne, L Krug, XF Wang, H Pang, C Watt, J Crawford, R Kratzke, E Vokes, HL
Kindler (2010). A phase II study of sorafenib in malignant mesothelioma:
Results of CALGB 30307. Journal of Thoracic Oncology 5(10), 1655-1661; PMID:
20736856.
-
J Salama, TE
Stinchcombe, L Gu, XF Wang, J. Bogart, J Crawford, MA Socinski, AW Blackstock,
EE Vokes (2011). Pulmonary toxicity in stage III non-small cell lung cancer
patients treated with high dose (74 Gy) 3-dimensional conformal thoracic
radiotherapy and concurrent chemotherapy following induction chemotherapy: A
secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J
Radiat Oncol Biol Phys 81(4), e269-274; PMID: 21477940.
-
GA Masters, XF
Wang, L Hodgson, E Vokes, M Green (2011). A phase II trial of high dose
carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support
followed by surgery and/or chest radiation in patients with stage III non-small
cell lung cancer: CALGB 9531. Lung Cancer 74, 258263; PMID: 21529989.
-
R Govindan, J
Bogart, T Stinchcombe, XFWang, L Hodgson, R Kratzke, J Garst, T Brotherton, E.
E. Vokes for the Cancer and Leukemia Group B (2011). A Randomized Phase II
Study of Pemetrexed, Carboplatin and Thoracic Radiation with or without
Cetuximab in Patients with Locally Advanced Unresectable Nonsmall Cell Lung
Cancer: Cancer and Leukemia Group B Trial 30407. Journal of Clinical Oncology
29(23), 3120-3125; PMID: 21747084.
-
A Kawaguchi,
GG Koch, XF Wang (2011). Stratified Multivariate Mann-Whitney Estimators for
the Comparison Of Two Treatments with Randomization Based Covariance
Adjustment. Statistics in Biopharmaceutical Research 3(2), 217-231.
-
YG Wu, XF Wang
(2011). Optimal Weight in Estimating the Receiver Operating Characteristic
Curve Area. Biometrical Journal 53(5), 764-778; PMID: 21805488.
-
AT Schroen, GR
Petroni, H Wang, MT Thielen, DJ Sargent, J Benedetti, W Cronin, L Wickerham, XF
Wang, R Gray, W Cohn, CL Slingluff Jr, B Djulbegovic (2011). Challenges to
accrual predictions to phase III cancer clinical trials: a survey of study
chairs and lead statisticians of 248 NCI sponsored trials. Clinical Trials
8(5), 591-600; PMID: 21878447.
-
MJ Edelman, XF
Wang, L Hodgson, R Christenson, E Vokes, R Kratzke (2011). Serum VEGF and
COX-2/5LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and
Leukemia Group B 150304.Journal of Thoracic Oncology 6(11); 1902-1906; PMID:
21964530.
-
T Jahan, L Gu,
R Kratzke, A Dudek, XF Wang, M Green, E Vokes, H Kindler for the Cancer and
Leukemia Group B (2011). Vatalanib (V) in malignant mesothelioma (MM): A phase
II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer Epub
2011 Dec 22; PMID: 22197613.
-
J Chen, XF
Wang, B Fan (2011). Nonparametric modeling auxiliary covariates in random
coefficient models. Communications in Statistics - Simulation and Computation
Epub 2011 Oct 5.
-
MJ Edelman, L
Hodgson, PY Rosenblatt, RH Christenson, E Vokes, XF Wang, R Kratzke, for the
Cancer and Leukemia Group B (2012). CYFRA 21-1 as a prognostic and predictive
marker in advanced non-small cell lung cancer in a prospective trial: CALGB
150304. Journal of Thoracic Oncology 7(4), 649-654.
-
AT Schroen, GR
Petroni, H Wang, MJ Thielen, R Gray, J Benedetti, XF Wang, DJ Sargent, DL
Wickerham, W Cronin, B Djulbegovic, CL Slingluff Jr (2012). Achieving
Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials
from US Cooperative Oncology Groups. Clinical Cancer Research 18(1), 256-262;
PMID: 21976533.